- Home
- NAVN vs CELC Comparison
NAVN vs CELC Comparison
Compare NAVN & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NAVN | CELC |
|---|---|---|
| Founded | 2015 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 3.1B |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | NAVN | CELC |
|---|---|---|
| Price | $8.90 | $114.28 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 10 | 8 |
| Target Price | $24.80 | ★ $106.63 |
| AVG Volume (30 Days) | ★ 1.2M | 527.9K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $30.17 | N/A |
| Revenue Next Year | $22.40 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.80 | $7.58 |
| 52 Week High | $20.27 | $120.32 |
Technical Indicators
Market Signals| Indicator | NAVN | CELC |
|---|---|---|
| Relative Strength Index (RSI) | 37.06 | 56.01 |
| Support Level | $8.83 | $97.75 |
| Resistance Level | $11.38 | $114.54 |
| Average True Range (ATR) | 0.67 | 5.14 |
| MACD | 0.04 | 0.36 |
| Stochastic Oscillator | 8.42 | 63.53 |
Price Performance
Historical ComparisonAbout NAVN Navan Inc.
Navan Inc is an end-to-end, AI-powered software platform built to simplify the world-wide business T&E experience, benefiting users, customers, and suppliers. Its leveraged technology to reimagine business travel. The company deliver delightful, personalized experiences for users, efficiency and control for customers, and direct market access for suppliers-all powered by its proprietary AI framework, Navan Cognition. Geographically, the company operates in United States, United Kingdom and Other countries, of which United States derives maximum revenue.
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.